Citations

Clear

158 citation(s) found for "Hartman, A-R".

Genetic architectures of proximal and distal colorectal cancer are partly distinct
Huyghe, Jeroen R. , Harrison, Tabitha A. , Figueiredo, Jane C. , Schmit, Stephanie L. , Chen, Sai , Barfield, Richard , Cross, Amanda J. , Diergaarde, Brenda , Duggan, David , Harlid, Sophia , Imaz, Liher , Kang, Hyun Min , Levine, David , Perduca, Vittorio , Perez‐Cornago, Aurora , Slattery, Martha L. , Duijnhoven, Fränzel J.B. van , Guelpen, Bethany Van , Anderson, Kristin E. , Arnau‐Collell, Coral, Banbury, Barbara L. , Berndt, Sonja I. , Bishop, D. Timothy , Boehm, Juergen , Boeing, Heiner , Brenner, Hermann , Buch, Stephan , Burnett‐Hartman, Andrea N. , Carr, Prudence R. , Castells, Antoni , Chang‐Claude, Jenny , Curtis, Keith R. , Chapelle, Albert de la , Easton, Douglas F. , English, Dallas R. , Gala, Manish , Gallinger, Steven , Gauderman, W. James, Goodman, Phyllis J. , Grove, John, Gsur, Andrea , Gunter, Marc J. , Haile, Robert W. , Hampe, Jochen , Hoffmeister, Michael , Hsu, Wan‐Ling, Huang, Wen‐Yi , Joshi, Amit D. , Kühn, Tilman , Küry, Sébastien , Lejbkowicz, Flavio, Li, Li , Lindblom, Annika , Lindor, Noralane M. , Markowitz, Sanford D. , Moreno, Lorena , Murphy, Neil , Nassir, Rami , Offit, Kenneth, Parfrey, Patrick S. , Pearlman, Rachel , Phipps, Amanda I. , Prentice, Ross L. , Qi, Lihong , Rennert, Gad , Rennert, Hedy S., Ríboli, Elio , Schafmayer, Clemens, Seminara, Daniela, Song, Mingyang , Su, Yu‐Ru, Thibodeau, Stephen N. , Thomas, Duncan C. , Trichopoulou, Antonia , Visvanathan, Kala, Vodička, Pavel , Vodičková, Ludmila, Weigl, Korbinian , Weinstein, Stephanie J. , Woods, Michael O. , Wu, Anna H. , Nickerson, Deborah A. , Scacheri, Peter C. , Kundaje, Anshul , Casey, Graham , Gruber, Stephen B. , Hayes, Richard B. , Peters, Ulrike , Visvanathan, Kala , Brenner, Hermann , Buchanan, Daniel D , Chan, Andrew T , Gsur, Andrea , Hampe, Jochen , Hoffmeister, Michael , Huang, Wen-Yi , Jenab, Mazda , Murphy, Neil , Peters, Ulrike , Rennert, Gad , English, Dallas R , Gunter, Marc J , Haile, Robert W , Harrison, Tabitha A , Van Guelpen, Bethany , Visvanathan, Kala , Kury, Sebastien , Bishop, D Timothy , Song, Mingyang , Hayes, Richard B , Perez-Cornago, Aurora , Nassir, Rami , Kundaje, Anshul , Riboli, Elio , Vodicka, Pavel , Diergaarde, Brenda , Lindblom, Annika , Bien, Stephanie A. , Hampel, Heather , Conti, David V. , Qu, Conghui , Lin, Yi , Baron, John A. , Sakoda, Lori C. , Schumacher, Fredrick R. , Toland, Amanda Ewart , Agudo, Antonio , Albanes, Demetrius , Alonso, M. Henar , Arndt, Volker , Bassik, Michael Cory , Bezieau, Stéphane , Boutron‐Ruault, Marie‐Christine , Brezina, Stefanie , Buchanan, Daniel D. , Caan, Bette J. , Campbell, Peter T. , Castellvı́-Bel, Sergi , Chan, Andrew T. , Chanock, Stephen Jacob , Feskens, Edith J. M. , Giles, Graham G. , Grady, William M. , Hopper, John L. , Hudson, Thomas J , Jenab, Mazda , Jenkins, Mark A. , Keku, Temitope O , Kooperberg, Charles , Marchand, Loı̈c Le , Li, Christopher I , Lieb, Wolfgang , Männistö, Satu , Milne, Roger L. , Ogino, Shuji , Panico, Salvatore , Pharoah, Paul D.P. , Platz, Elizabeth A. , Potter, John D. , Raskin, Leon , Schoen, Robert E. , Tangen, Catherine M. , Ulrich, Cornelia M. , Vymetalkova, Veronika Polakova , White, Emily E. , Wolk, Alicja , Abecasis, Gonçalo R. , Hsu, Li , Moreno, Vı́ctor , Newcomb, Polly A.

Mayo Clinic

Gut | February 25, 2021 | Volume: 70 | Issue: 7 | Pages: 1325-1334

10.1136/gutjnl-2020-321534 | PMID 33632709 Get It

Objective An understanding of the etiologic heterogeneity of colorectal cancer (CRC) is critical for improving precision prevention, including individualized screening recommendations and the discovery of novel drug targets and repurposable drug candidates for chemoprevention. Known differences in molecular characteristics and environmental risk factors among tumors arising in different locations of the colorectum suggest partly distinct mechanisms of carcinogenesis. The extent to which the contribution of inherited genetic risk factors for CRC differs by anatomical subsite of the primary tumor has not been examined. Design To identify new anatomical subsite-specific risk loci, we performed genome-wide association study (GWAS) meta-analyses including data of 48 214 CRC cases and 64 159 controls of European ancestry. We characterised effect heterogeneity at CRC risk loci using multinomial modelling. Results We identified 13 loci that reached genome-wide significance (p<5×10 −8 ) and that were not reported by previous GWASs for overall CRC risk. Multiple lines of evidence support candidate genes at several of these loci. We detected substantial heterogeneity between anatomical subsites. Just over half (61) of 109 known and new risk variants showed no evidence for heterogeneity. In contrast, 22 variants showed association with distal CRC (including rectal cancer), but no evidence for association or an attenuated association with proximal CRC. For two loci, there was strong evidence for effects confined to proximal colon cancer. Conclusion Genetic architectures of proximal and distal CRC are partly distinct. Studies of risk factors and mechanisms of carcinogenesis, and precision prevention strategies should take into consideration the anatomical subsite of the tumour.
Development and initial validation of a deep learning algorithm to quantify histological features in colorectal carcinoma including tumour budding/poorly differentiated clusters
Pai, Reetesh K. , Rosty, Christophe , Shivji, Sameer , Kirsch, Richard , Pai, Rish K. , Rosty, Christophe , Shivji, Sameer , Pai, R K , Hartman, Douglas J. , Schaeffer, David F.

Mayo Clinic

Histopathology | February 16, 2021 | Volume: 79 | Issue: 3 | Pages: 391-405

10.1111/his.14353 | PMID 33590485 Get It

AimsTo develop and validate a deep learning algorithm to quantify a broad spectrum of histological features in colorectal carcinoma.Methods and resultsA deep learning algorithm was trained on haematoxylin and eosin‐stained slides from tissue microarrays of colorectal carcinomas (N = 230) to segment colorectal carcinoma digitised images into 13 regions and one object. The segmentation algorithm demonstrated moderate to almost perfect agreement with interpretations by gastrointestinal pathologists, and was applied to an independent test cohort of digitised whole slides of colorectal carcinoma (N = 136). The algorithm correctly classified mucinous and high‐grade tumours, and identified significant differences between mismatch repair‐proficient and mismatch repair‐deficient (MMRD) tumours with regard to mucin, inflammatory stroma, and tumour‐infiltrating lymphocytes (TILs). A cutoff of >44.4 TILs per mm2 carcinoma gave a sensitivity of 88% and a specificity of 73% in classifying MMRD carcinomas. Algorithm measures of tumour budding (TB) and poorly differentiated clusters (PDCs) outperformed TB grade derived from routine sign‐out, and compared favourably with manual counts of TB/PDCs with regard to lymphatic, venous and perineural invasion. Comparable associations were seen between algorithm measures of TB/PDCs and manual counts of TB/PDCs for lymph node metastasis (all P < 0.001); however, stronger correlations were seen between the proportion of positive lymph nodes and algorithm measures of TB/PDCs. Stronger associations were also seen between distant metastasis and algorithm measures of TB/PDCs (P = 0.004) than between distant metastasis and TB (P = 0.04) and TB/PDC counts (P = 0.06).ConclusionsOur results highlight the potential of deep learning to identify and quantify a broad spectrum of histological features in colorectal carcinoma.
Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium
Morra, Anna , Jung, Audrey , Behrens, Sabine , Keeman, Renske , Ahearn, Thomas U. , Arndt, Volker , Augustinsson, Annelie , Auvinen, Päivi , Becher, Heiko , Beckmann, Matthias W. , Bojesen, Stig E. , Bolla, Manjeet K. , Brenner, Hermann , Camp, Nicola J. , Campa, Daniele , Castelao, Jose E. , Choi, Ji‐Yeob , Cox, Angela , Easton, Douglas F. , Eccles, Diana M., Egan, Kathleen M. , Evans, D. Gareth , Fasching, Peter A. , Flyger, Henrik, Gago-Domínguez, Manuela , Gapstur, Susan M. , Gaudet, Mia M. , Grip, Mervi, Guénel, Pascal , Haiman, Christopher A. , Håkansson, Niclas , Hamann, Ute, Hartman, Mikael , Heyworth, Jane , Hoppe, Reiner , Hopper, John L. , Hunter, David J. , Jager, Agnes , Jakimovska, Milena , Janni, Wolfgang , Koutros, Stella , Kristensen, Vessela N. , Lambrechts, Diether , Li, Jingmei , Lindblom, Annika , Mannermaa, Arto , Manoochehri, Mehdi, Margolin, Sara , Mariapun, Shivaani, Mavroudis, Dimitrios, Muranen, Taru , Newman, William G. , Noh, Dong‐Young , Nordestgaard, Børge G. , Obi, Nadia , Olsson, Håkan , Park‐Simon, Tjoung‐Won , Petridis, Christos , Plaseska‐Karanfilska, Dijana , Rashid, Muhammad Usman , Rennert, Gad , Rennert, Gad , Rhenius, Valerie , Romero, Atocha , Saloustros, Emmanouil , Sawyer, Elinor J. , Schneeweiß, Andreas , Schwentner, Lukas , Shah, Mitul , Shen, Chen‐Yang , Tollenaar, Rob A.�E.�M. , Tomlinson, Ian , Torres, Diana , Vachon, Celine M. , Wang, Qin , Wang, Sophia , Williams, Justin A. , Winqvist, Robert , Wu, Anna H. , Yoo, Keun-Young, Yu, Jyh‐Cherng , Zheng, Wei , Yang, Xiaohong R. , Eliassen, A. Heather , García‐Closas, Montserrat , Teo, Soo‐Hwang , Chang‐Claude, Jenny , Eccles, Diana , Khaw, Kay‐Tee , Lambrechts, Diether , Arndt, Volker , Augustinsson, Annelie , Brenner, Hermann , Camp, Nicola J , Canzian, Federico , Cox, Angela , Dunning, Alison M , Evans, D Gareth , Fasching, Peter A , Gago-Dominguez, Manuela , García-Sáenz, José A , Gaudet, Mia M , Giles, Graham G , Guénel, Pascal , Hall, Per N , Hart, Steven N , Hartman, Mikael , Ito, Hidemi , Jager, Agnes , Jakubowska, Anna , Janni, Wolfgang , Kaaks, Rudolf , Kapoor, Pooja Middha , Koutros, Stella , Lambrechts, Diether , Li, Jingmei , Matsuo, Keitaro , Milne, Roger L , Muranen, Taru A , Newman, William G , Park-Simon, Tjoung-Won , Pharoah, Paul D P , Rennert, Gad , Rennert, Gad , Rhenius, Valerie , Romero, Atocha , Saloustros, Emmanouil , Schneeweiss, Andreas , Scott, Christopher , Southey, Melissa C , Stram, Daniel O. , Tamimi, Rulla M , Tomlinson, Ian , Torres, Diana , Vachon, Celine M. , Wolk, Alicja , Ziogas, Argyrios , Holmes, Michelle D , García-Closas, Montserrat , Teo, Soo H , Schmidt, Marjanka K , Chang-Claude, Jenny , Lambrechts, Diether , Behrens, Sabine , Eccles, Diana , Keeman, Renske , Zheng, Wei , Wang, Sophia S , Jung, Audrey Y , Becher, Heiko , Eliassen, A Heather , Håkansson, Niclas , Rashid, Muhammad U , Bojesen, Stig E , Lindblom, Annika , Plaseska-Karanfilska, Dijana , Sawyer, Elinor J , Anton‐Culver, Hoda , Freeman, Laura E. Beane , Blomqvist, Carl , Briceño, Ignacio , Brucker, Sara Yvonne , Canzian, Federico , Chanock, Stephen Jacob , Clarke, Christine L. , Couch, Fergus J. , Cross, Simon S. , Czene, Kamila , Dörk, Thilo , Dunning, Alison M. , Dwek, Miriam , García-Sáenz, José Á. , Giles, Graham G. , Han, Sileny , Hart, Steven N. , Ito, Hidemi , Jakubowska, Anna , Kaaks, Rudolf , Kang, Daehee , Middha, Pooja , Kitahara, Cari M. , Kraft, Peter , Lacey, James V. , Marchand, Loı̈c Le , Lubiński, Jan , Lush, Michael J. , Manoochehri, Mehdi, Matsuo, Keitaro , Milne, Roger L. , Olshan, Andrew F. , Pharoah, Paul D.P. , Presneau, Nadège , Scott, Christopher G. , Shu, Xiao‐Ou , Southey, Melissa C. , Tamimi, Rulla M. , Tapper, William , Troester, Melissa A. , Truong, Thérèse , Wolk, Alicja , Ziogas, Argyrios , Schmidt, Marjanka K.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 26, 2021 | Volume: 30 | Issue: 4 | Pages: 623-642

10.1158/1055-9965.epi-20-0924 | PMID 33500318 Get It

Abstract Background: It is not known whether modifiable lifestyle factors that predict survival after invasive breast cancer differ by subtype. Methods: We analyzed data for 121,435 women diagnosed with breast cancer from 67 studies in the Breast Cancer Association Consortium with 16,890 deaths (8,554 breast cancer specific) over 10 years. Cox regression was used to estimate associations between risk factors and 10-year all-cause mortality and breast cancer–specific mortality overall, by estrogen receptor (ER) status, and by intrinsic-like subtype. Results: There was no evidence of heterogeneous associations between risk factors and mortality by subtype (Padj &gt; 0.30). The strongest associations were between all-cause mortality and BMI ≥30 versus 18.5–25 kg/m2 [HR (95% confidence interval (CI), 1.19 (1.06–1.34)]; current versus never smoking [1.37 (1.27–1.47)], high versus low physical activity [0.43 (0.21–0.86)], age ≥30 years versus &lt;20 years at first pregnancy [0.79 (0.72–0.86)]; &gt;0–&lt;5 years versus ≥10 years since last full-term birth [1.31 (1.11–1.55)]; ever versus never use of oral contraceptives [0.91 (0.87–0.96)]; ever versus never use of menopausal hormone therapy, including current estrogen–progestin therapy [0.61 (0.54–0.69)]. Similar associations with breast cancer mortality were weaker; for example, 1.11 (1.02–1.21) for current versus never smoking. Conclusions: We confirm associations between modifiable lifestyle factors and 10-year all-cause mortality. There was no strong evidence that associations differed by ER status or intrinsic-like subtype. Impact: Given the large dataset and lack of evidence that associations between modifiable risk factors and 10-year mortality differed by subtype, these associations could be cautiously used in prognostication models to inform patient-centered care.
Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis
Spratt, Daniel E. , Malone, Shawn , Roy, Soumyajit , Grimes, Scott, Eapen, Libni , Morgan, Scott C. , Malone, Julia, Craig, Julia , Dess, Robert T. , Kishan, Amar U. , Mehra, Rohit , Kaffenberger, Samuel D. , Reichert, Zachery R. , Alumkal, Joshi J. , Michalski, Jeff M. , Lee, W. Robert , Pisansky, Thomas M. , Feng, Felix Y. , Shipley, William U. , Schipper, Mathew J., Roach, Mack , Sun, Yilun , Lawton, C.A., Spratt, Daniel E , Dess, Robert T , Jackson, Will , Hartman, Holly , Morgan, Todd M. , Sandler, Howard M.

Mayo Clinic

Journal of Clinical Oncology | December 4, 2020 | Volume: 39 | Issue: 2 | Pages: 136-144

10.1200/jco.20.02438 | PMID 33275486 Get It

PURPOSEThere remains a lack of clarity regarding the influence of sequencing of androgen deprivation therapy (ADT) and radiotherapy (RT) on outcomes in prostate cancer (PCa). Herein, we evaluate the optimal sequencing of ADT with prostate-directed RT in localized PCa.METHODSMEDLINE (1966-2018), Embase (1982-2018), ClinicalTrials.gov, and conference proceedings (1990-2018) were searched to identify randomized trials evaluating the sequencing, but not duration, of ADT with RT. Two randomized phase III trials were identified, and individual patient data were obtained: Ottawa 0101 and NRG Oncology's Radiation Therapy Oncology Group 9413. Ottawa 0101 randomly assigned patients to neoadjuvant or concurrent versus concurrent or adjuvant short-term ADT. Radiation Therapy Oncology Group 9413, a 2 × 2 factorial trial, included a random assignment of neoadjuvant or concurrent versus adjuvant short-term ADT. The neoadjuvant or concurrent ADT arms of both trials were combined into the neoadjuvant group, and the arms receiving adjuvant ADT were combined into the adjuvant group. The primary end point of this meta-analysis was progression-free survival (PFS).RESULTSThe median follow-up was 14.9 years. Overall, 1,065 patients were included (531 neoadjuvant and 534 adjuvant). PFS was significantly improved in the adjuvant group (15-year PFS, 29% v 36%, hazard ratio [HR], 1.25 [95% CI, 1.07 to 1.47], P = .01). Biochemical failure (subdistribution HR [sHR], 1.37 [95% CI, 1.12 to 1.68], P = .002), distant metastasis (sHR, 1.40 [95% CI, 1.00 to 1.95], P = .04), and metastasis-free survival (HR, 1.17 [95% CI, 1.00 to 1.37], P = .050) were all significantly improved in the adjuvant group. There were no differences in late grade ≥ 3 gastrointestinal (2% v 3%, P = .33) or genitourinary toxicity (5% v 5%, P = .76) between groups.CONCLUSIONThe sequencing of ADT with prostate-directed RT has significant association with long-term PFS and MFS in localized PCa. Our findings favor use of an adjuvant over a neoadjuvant approach, without any increase in long-term toxicity.
Abstract CT291: The PATHFINDER Study: Assessment of the implementation of an investigational multi-cancer early detection test into clinical practice
Nadauld, Lincoln , McDonnell, Charles H. , Liu, Minetta C. , Hudnut, Andrew , Whittington, Richard, Tierney, Joanna, Lipson, Jafi A. , Lopatin, Margarita , Fung, Eric T. , Hartman, Anne‐Renee , Oxnard, Geoffrey R. , Klein, Eric A. , Beer, Tomasz M. , Schrag, Deborah , Taylor, Bruce , Tierney, Joanna, Marinac, Catherine R. , Chung, Karen

Mayo Clinic

Cancer Research | September 4, 2020 | Volume: 80 | Issue: 16_Supplement | Pages: CT291-CT291

10.1158/1538-7445.am2020-ct291 Get It

Abstract Background: Early detection decreases patient mortality for many cancers, but prevailing paradigms focus on distinct screening modalities for each cancer type. A minimally invasive test that detects multiple tumor types could substantially reduce cancer mortality and improve screening efficiency. In preliminary studies, we showed that a targeted methylation cell-free DNA (cfDNA) test can detect cancer and determine the tissue of origin (TOO) of abnormally methylated cfDNA with high sensitivity and specificity; however, blood was collected at the time of diagnosis and results were not disclosed to inform care. The current study includes disclosure of results to the study investigator to understand the care pathways prompted by a “signal detected” test result, and the benefits, harms, and burdens associated with a multi-cancer detection test. Methods: PATHFINDER (NCT04241796) is a prospective, longitudinal, multi-center clinical study. Approximately 6,200 participants with varying levels of cancer risk will be enrolled at 5-10 clinical sites in the United States. Participants must be ≥50 years of age. If participants have at least 1 of the following–a smoking history of ≥100 cigarettes, a genetic cancer predisposition, or a history of invasive or hematologic malignancy with definitive treatment completed &gt;3 years prior to enrollment–they are eligible for the Elevated Risk Cohort (n = 4340); otherwise, they are eligible for the Non-Elevated Risk Cohort (n = 1860). Individuals being evaluated for cancer or who have a history of invasive or hematologic malignancy within 3 years of enrollment will be excluded. Blood drawn at study sites will be analyzed at GRAIL, Inc. (Menlo Park, CA). Participants and study investigators will be informed of the test results. Participants with “signal not detected” results will be advised to continue routine clinical care, including age- and risk-based cancer screening. Those with “signal detected” test results will be informed of the predicted origin and undergo diagnostic evaluation. The primary study objective is to determine the extent of diagnostic testing required to achieve diagnostic resolution following a “signal detected” test result, defined as the date when the study investigator determines to end diagnostic evaluation triggered by a “signal detected” test result. Health resource utilization, the number and types of tests and time required to reach this point, is the primary endpoint. Secondary objectives include evaluation of test performance (specificity, positive predictive value, and TOO accuracy), and assessment of participants' perceptions about the test and changes in anxiety and health-related quality of life. Exploratory aims include assessment of the number and types of invasive cancer diagnoses among participants with “signal not detected” test results and changes in attitude toward adherence to guideline-recommended screening. Citation Format: Lincoln Nadauld, Charles H. McDonnell III, Minetta C. Liu, Eric Klein, Tomasz M. Beer, Deborah Schrag, Andrew G. Hudnut, Richard Whittington, Bruce Taylor, Joanna Tierney, Catherine Marinac, Jafi Lipson, Margarita Lopatin, Karen C. Chung, Eric Fung, Anne-Renee Hartman, Geoffrey R. Oxnard. The PATHFINDER Study: Assessment of the implementation of an investigational multi-cancer early detection test into clinical practice [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr CT291.
Abstract CT021: Prediction of cancer and tissue of origin in individuals with suspicion of cancer using a cell-free DNA multi-cancer early detection test
Thiel, David D. , Chen, Xiaoji , Yecies, Jessica L., Wu, Tony J. , Zhang, Quan , Liu, Hai , Fung, Eric T. , Seiden, Michael V., Liu, Minetta C. , Oxnard, Geoffrey R. , Aravanis, Alexander M. , Hartman, Anne‐Renee , Kurtzman, Kathryn N. , Zhang, Nan , Hubbell, Earl , Klein, Eric A.

Mayo Clinic

Cancer Research | September 4, 2020 | Volume: 80 | Issue: 16_Supplement | Pages: CT021-CT021

10.1158/1538-7445.am2020-ct021 Get It

Abstract Background: The Circulating Cell-free Genome Atlas study (NCT02889978) is a multi-center, case-control, observational study with longitudinal follow-up (n=15,254; 56% cancer, 44% non-cancer) to support development of a cell-free DNA (cfDNA) multi-cancer early detection test. Previously, we reported that a targeted methylation assay detected and localized &gt;20 cancer types at &gt;99% specificity in individuals with cancer.1,2 Here, we report prediction of cancer (presence/absence) and tissue of origin (TOO) in individuals enrolled with clinical suspicion of cancer but without pathologic diagnosis or treatment at time of enrollment. Methods: Plasma cfDNA from blood samples collected prior to clinical diagnosis was subjected to targeted methylation sequencing. Samples were divided into a training set and an independent validation set to train and validate a machine learning classifier to assess cancer and predict TOO. Performance was assessed in a subset of participants enrolled with suspicion of cancer; subsequently, cancer was confirmed by evaluating a pathologic specimen. Results: Participants being evaluated for suspicion of cancer were classified as confirmed cancer (&gt;20 cancer types; n=164 in training, n=75 in validation) or confirmed non-cancer (n=49 training, n=15 validation). In the confirmed non-cancer group, all training and validation samples were correctly predicted as non-cancer (100% specificity). In the confirmed cancer group, cancer detection across all stages was 40.2% (66/164; 95% confidence interval [CI], 32.7-48.2%) in training and 46.7% (35/75; 95% CI, 35.1-58.6%) in validation. Excluding stage I renal cancers (where detection/tumor fraction is low in plasma and which comprised 20% of participants in this subset) detection across stages was 50.4% (66/131; 95% CI, 41.5-59.2%) and 59.3% (35/59; 95% CI, 45.7-71.9%), respectively. In stages II and above, detection was 70.7% (58/82; 95% CI, 59.6-80.3%) and 78.9% (30/38; 95% CI, 62.7-90.4%), respectively. For detected cancers, TOO was predicted in 93.9% (62/66) samples in training and 100% (35/35) in validation. Of those with a TOO call, accuracy was 85.5% (53/62; 95% CI, 74.2-93.1%) and 97.1% (34/35; 95% CI, 85.1-99.9%), respectively. Conclusion: A cfDNA multi-cancer detection test has shown the potential to predict cancer and TOO in individuals with suspicion of cancer ahead of histologic diagnosis with performance comparable to those with confirmed cancer at the time of blood collection. This was achieved with high specificity and TOO accuracy. The high specificity suggests that the false positive rate could be comparable in populations with average versus higher risk (suspicion) of cancer. These findings suggest that a cfDNA multi-cancer detection test could accelerate the diagnostic resolution of suspicion of cancer. References: 1. Oxnard GR, et al. ASCO Breakthrough Meeting 2019; Abstract 44. 2. Oxnard GR, et al. ESMO Annual Meeting 2019; Abstract 5639. Citation Format: David D. Thiel, Xiaoji Chen, Kathryn N. Kurtzman, Jessica Yecies, Tony Wu, Quan Zhang, Hai Liu, Nan Zhang, Eric T. Fung, Michael V. Seiden, Minetta C. Liu, Geoffrey R. Oxnard, Earl Hubbell, Alexander M. Aravanis, Anne-Renee Hartman, Eric A. Klein. Prediction of cancer and tissue of origin in individuals with suspicion of cancer using a cell-free DNA multi-cancer early detection test [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr CT021.
Serum IgG4 Subclass Deficiency Defines a Distinct, Commonly Encountered, Severe Inflammatory Bowel Disease Subtype
Koutroumpakis, Filippos , Yadav, Dhiraj , Machicado, Jorge D. , Ahsan, Maaz, Rivers, Claudia Ramos, Tan, Xiaoqing , Schwartz, Marc , Proksell, Siobhan, Johnston, Elyse, Dueker, Jeffrey, Barrie, Arthur, Harrison, Janet, Dunn, Michael A. , Konnikova, Liza , Din, Hasieb, Babichenko, Dmitriy , Tang, Gong , Binion, David G. , Phillips, Anna Evans , Hashash, Jana G. , Harrison, Janet, Hartman, Douglas J.

Mayo Clinic

Inflammatory Bowel Diseases | September 3, 2020 | Volume: 27 | Issue: 6 | Pages: 855-863

10.1093/ibd/izaa230 | PMID 32879976 Get It

Abstract Background Immunoglobulin G subclass 4 (IgG4) is hypothesized to play an immunomodulatory role, downregulating humoral immune responses. The role of this anti-inflammatory molecule in inflammatory bowel disease (IBD) has not been fully characterized. We sought to define alterations in serum IgG4 in patients with IBD and their association with multiyear disease severity. Methods We analyzed metadata derived from curated electronic health records from consented patients with IBD prospectively followed at a tertiary center over a 10-year time period. Patients with IBD with IgG4 serum levels available formed the study population. Demographics and multiyear clinical data were collected and analyzed. We stratified patients with IBD with low, normal, or high serum IgG4 levels. Results We found IgG4 characterized in 1193 patients with IBD and low IgG4 levels in 233 patients (20%) and elevated IgG4 levels in 61 patients (5%). An IgG4 deficiency did not significantly correlate with other antibody deficiencies. In a multiple Poisson regression analysis, low IgG4 was associated with more years on biologic agents (P = 0.002) and steroids (P = 0.049) and more hospital admissions (P &lt; 0.001), clinic visits (P = 0.010), outpatient antibiotic prescriptions (P &lt; 0.001), and CD-related surgeries (P = 0.011) during the study period after controlling for certain confounders. Elevated IgG4 was only associated with primary sclerosing cholangitis (P = 0.011). A cohort of patients with IgG4-deficient severe IBD received intravenous Ig replacement therapy, which benefited and was continued in 10 out of 11 individuals. Conclusions An IgG4 subclass deficiency, distinct from other antibody deficiencies, occurred commonly in a referral IBD population and was associated with multiple markers of disease severity. This is the first association of IgG4 subclass deficiency with an inflammatory disease process. Further work is needed to define the mechanistic role of IgG4 deficiency in this severe IBD subgroup.
Abstract IA02: Multicancer detection of early-stage cancers with simultaneous tissue localization using a plasma cfDNA-based targeted methylation assay
Hartman, Anne‐Renee , Oxnard, Geoffrey R. , Seiden, Michael V., Venn, Oliver, Jamshidi, Arash , Zhang, Nan , Beausang, John F., Gross, Samuel, Fung, Eric T. , Allen, Brian, Fields, Alexander P. , Liu, Hai , Richards, Donald , Aravanis, Alexander M. , Liu, Minetta C. , Klein, Eric A. , Hubbell, Earl , Gross, Samuel, Kurtzman, Kathryn N. , Sekeres, Mikkael A. , Yu, Peter Paul

Mayo Clinic

Clinical Cancer Research | June 16, 2020 | Volume: 26 | Issue: 11_Supplement | Pages: IA02-IA02

10.1158/1557-3265.liqbiop20-ia02 Get It

Abstract Background: Earlier cancer detection could identify tumors when they are more treatable and thus may improve clinical outcomes. A blood-based multicancer early detection test using circulating tumor cell-free DNA (cfDNA) offers the potential to address this unmet need. Our previous discovery work identified whole-genome bisulfite sequencing as outperforming whole-genome and targeted sequencing approaches for multicancer detection across stages. We thus developed a targeted methylation (TM) assay for multicancer detection and tissue-of-origin (TOO) localization. Methods: Participants were from the Circulating Cell-free Genome Atlas (CCGA; NCT02889978) and STRIVE (NCT03085888) studies, both prospective, multicenter, observational studies with longitudinal follow-up. cfDNA samples spanning &gt;20 cancer types of all stages were divided into a cross-validated training set and an independent validation set; there were 3,583 evaluable samples in training (1,530 cancer; 2,053 noncancer) and 1,803 in validation (678 cancer; 1,125 noncancer). Performance in a prespecified set of 12 high-signal cancers was also reported (anus, bladder, colon/rectum, esophagus, head and neck, liver/bile-duct, lung, lymphoma, ovary, pancreas, plasma cell neoplasm, stomach). This multicancer early detection test evaluated cfDNA for the presence of cancer and localization of TOO; the TM classifier was trained to target &gt;99% specificity. Precision was defined as the fraction of correct calls. Results: Participants with and without cancer were similar in age. Specificity across all cancer types in the training and validation sets was 99.8% (95% CI, 99.2-99.9%) and 99.3% (98.3-99.8%), respectively, which reflects a consistent (P=0.292) false positive rate of &lt;1%. Across all cancer types, aggregate sensitivity was also consistent between the training and validation sets (55% [53-58%] and 55% [51-59], respectively; P=0.897). In the validation set, aggregate sensitivity in the prespecified group was 76% (73-78%); detection was 39% (27–52%) in stage I (n=62), 69% (56–80%) in stage II (n=62), 83% (75–90%) in stage III (n=102), and 92% (86–96%) in stage IV (n=130). Overall, the classifier assigned a TOO across &gt;20 cancer types in 96% of samples (344/359); of these, the TOO was correct in 93% (321/344) of cases, which was consistent with training set analyses. Conclusions: This multicancer early detection test detected cancer signal across &gt;20 cancer types with a single, fixed, low false positive rate and highly accurate TOO localization. Importantly, results in the independent validation set were consistent with the training set, demonstrating the robustness of machine learning classifier training, and confirms that data were not overfitted. These data support the feasibility of a single blood-based test that can detect multiple cancers, supporting further clinical development in preparation for the return of results. Citation Format: Anne-Renee Hartman, Geoffrey Oxnard, Eric Klein, Michael Seiden, Earl Hubbell, Oliver Venn, Arash Jamshidi, Nan Zhang, John Beausang, Samuel Gross, Kathryn Kurtzman, Eric Fung, Brian Allen, Alexander Fields, Hai Liu, Mikkael Sekeres, Donald Richards, Peter Yu, Alexander Aravanis, Minetta Liu. Multicancer detection of early-stage cancers with simultaneous tissue localization using a plasma cfDNA-based targeted methylation assay [abstract]. In: Proceedings of the AACR Special Conference on Advances in Liquid Biopsies; Jan 13-16, 2020; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(11_Suppl):Abstract nr IA02.
Abstract P5-01-01: Blood-based cancer detection in plasma cell-free DNA (cfDNA): Evaluating clinical and pathologic tumor characteristics in participants with breast cancer
Liu, Minetta C. , Visscher, Daniel W., Kopp, Karla, Shaknovich, Rita , Chen, Xiaoji , Patel, Shilpen, Brooks, Jacqueline D., Cosenza, Carlo R., Lipson, Jafi A. , Richards, Donald , Liu, Hai , Venn, Oliver, Bredno, Joerg , Fung, Eric T. , Hartman, Anne‐Renee , Carter, Jodi M. , Kurtzman, Kathryn N. , Couch, Fergus J. , Zhao, Dong

Mayo Clinic

Cancer Research | March 26, 2020 | Volume: 80 | Issue: 4_Supplement | Pages: P5-01-01-P5-01-01

10.1158/1538-7445.sabcs19-p5-01-01 Get It

Abstract Background The Circulating Cell-free Genome Atlas (CCGA; NCT02889978) study is a prospective, multi-center, observational, case-control study with longitudinal follow-up to support the development of a plasma cfDNA-based multi-cancer early detection assay. We previously reported that the fraction of tumor-derived cfDNA fragments in plasma (estimated tumor fraction [TF]) is associated with detection of multiple cancer types using a prototype whole-genome bisulfite sequencing (WGBS) assay in a pre-specified substudy. In addition, detectability of breast cancer varied by hormone-receptor (HR) status: HR negative (HR-) breast cancer had a higher detection rate than the overall breast cancer cohort. Here, we performed a planned in-depth analysis of the breast cancer cohort to understand the main clinical and biological determinants of detectability using our WGBS assay. Methods Blood samples were prospectively collected from participants (pts) with newly-diagnosed, untreated breast cancer. In a pre-specified CCGA substudy, 511 (31.4%) of 1,628 pts had a clinicopathologic diagnosis of breast cancer (any stage, excluding stage 0) and a WGBS result. Pre-specified biological and clinical factors were assessed for correlation with TF: clinical stage, pathologic N stage, lesion size (by imaging), T stage, histologic grade, hormone receptor (HR) status, and proliferative rate (Ki-67 by IHC [MIB-1 clone]) via univariate and multivariate analyses. Ki-67 was obtained from pathology reports provided by enrollment sites and also assessed centrally (Mayo Clinic [Rochester, MN]). Stage-specific differences in detection rates between HR positive (HR+) and HR- breast cancers due to biological differences such as histologic grade and/or proliferative rate was also assessed. Results Of 511 pts, 94 (18.4%; 48.9% HR- and 12.3% in HR+) had WGBS-detected cancer. Higher TF was significantly associated with cancer detection (p&lt;0.001). In univariate analyses, the variables significantly associated with TF were clinical stage, pathological N stage, and histologic grade (p&lt;0.001 each). Primary lesion size was modestly correlated with TF (all stages combined: Spearman's correlation coefficient rs=0.4, p&lt;0.001), and when grouped by early and late stages (stages I/II: rs=0.27, p&lt;0.01; stages III/IV: rs=0.50, p&lt;0.01); clinical T stage was significantly associated with TF only when all stages were combined (p&lt;0.001). Proliferative rate (Ki-67) was positively correlated with TF at stages I/II (rs=0.29, p&lt;0.05) but not III/IV (rs=-0.24, p=0.34); Ki-67 results obtained through Mayo were similar to that from enrollment sites (Pearson’s correlation coefficient rp=0.68, p&lt;0.001). HR- breast cancers had significantly higher TF versus HR+ breast cancers only at stage II (p&lt;0.001). In addition, compared to HR+ breast cancers, HR- breast cancers had a significantly higher proportion of high histologic grade (p&lt;0.001 at stages I and II) and proliferative rate at earlier stages (p&lt;0.05 at stages I, II, and III). In the multivariate analysis, clinical stage (stage III vs I and IV vs I) and HR status remained the most significantly associated with TF (p&lt;0.001 each). Conclusions Using a prototype methylation-based plasma cfDNA cancer detection assay, TF was found to be associated with detection, and with clinical and biological features of breast cancer. Features routinely used to assess clinical aggressiveness (eg, HR- status and histologic grade) also demonstrated stage-specific associations with TF. Given the known relationship between TF and detection, these data suggest that clinical and biological cancer features may also provide insight into the variability of cancer detection using plasma-based cfDNA tests. Citation Format: Minetta C. Liu, Jodi M. Carter, Daniel W. Visscher, Karla Kopp, Rita Shaknovich, Xiaoji Chen, Kathryn N. Kurtzman, Shilpen Patel, Jacqueline D. Brooks, Carlo R. Cosenza, Jafi A. Lipson, Donald A. Richards, Fergus J. Couch, Zhao Dong, Hai Liu, Oliver Venn, Joerg Bredno, Eric T. Fung, Anne-Renee Hartman. Blood-based cancer detection in plasma cell-free DNA (cfDNA): Evaluating clinical and pathologic tumor characteristics in participants with breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P5-01-01.